Drugs / OLN324
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07484074 | Feb → Oct 2025 | diabetic macular edema, wet macular degeneration | Ollin Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLN324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07484074 ↗ |
| Route | Intravitreal | “Intravitreal Injection” NCT07484074 ↗ |